Rigel Pharmaceuticals, Inc. RIGL
43.91 USD +1.86 (+4.42%)
At closeNov 10, 2026, 4:27 PM EST
43.91 0.00 0.00%
After hours · Nov 10, 4:27 PM ET
41.91 Day range 44.14
24.95 52-week range 52.61
- YTD
- +2.52%
- 1 year
- +27.09%
News
seekingalpha.com Rigel Pharmaceuticals: Top-Line Momentum Meets Margin Compression In Q3 Rigel Pharmaceuticals shows strong top-line growth but faces margin compression, with Q3 revenues up 16.5% year-over-year and net income down 52.7%. VEPPANU's launch is promising, generating $6.6…
prnewswire.com Rigel to Present at the Jefferies Global Healthcare Conference in London SOUTH SAN FRANCISCO, Calif., Nov. 10, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today…
benzinga.com Citigroup Maintains Buy on Rigel Pharmaceuticals, Raises Price Target to $86 Citigroup analyst Yigal Nochomovitz maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and raises the price target from $83 to $86.
marketbeat.com Rigel Pharmaceuticals Q3 Earnings Call Highlights Rigel Pharmaceuticals NASDAQ: RIGL reported record quarterly product sales in the third quarter of 2026, helped by the launch of breast cancer treatment VEPPANU, while net income declined as spending…
benzinga.com Cantor Fitzgerald Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $47 Cantor Fitzgerald analyst Kristen Kluska maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Neutral and raises the price target from $43 to $47.
seekingalpha.com Rigel Pharmaceuticals, Inc. (RIGL) Q3 2026 Earnings Call Transcript Rigel Pharmaceuticals, Inc. (RIGL) Q3 2026 Earnings Call Transcript
zacks.com Rigel Pharmaceuticals (RIGL) Misses Q3 Earnings Estimates Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $0.65 per share, missing the Zacks Consensus Estimate of $0.87 per share. This compares to earnings of $1.46 per share a year ago.
benzinga.com Rigel Pharmaceuticals Q3 2026 Earnings Call Transcript Rigel Pharmaceuticals (NASDAQ:RIGL) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide…- benzinga.com Rigel Pharmaceuticals Raises FY2026 Sales Guidance from $285.000M-$295.000M to $290.000M-$295.000M vs $305.733M Est Rigel Pharmaceuticals (NASDAQ:RIGL) raises FY2026 sales outlook from $285.000 million-$295.000 million to $290.000 million-$295.000 million vs $305.733 million estimate.
prnewswire.com Rigel Reports Third Quarter 2026 Financial Results Third quarter 2026 total revenues of $80.9 million, including net product sales of $72.3 million and contract revenues from collaborations of $8.6 million, and net income of $13.2 million VEPPANU™…
prnewswire.com Rigel Announces Oral Presentation of Phase 1b Data for R289 in Patients with Lower-Risk MDS at the 68th American Society of Hematology Annual Meeting and Exposition Oral presentation to feature updated data from the dose escalation and dose expansion phases of the ongoing Phase 1b study evaluating R289, Rigel's dual IRAK1/4 inhibitor, in patients with relapsed…
prnewswire.com Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial Results SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2026 financial results after market close…
seekingalpha.com Rigel Pharmaceuticals: Turning Big Pharma's Castoffs Into A Growth Engine Rigel Pharmaceuticals is evolving into a multi-product oncology platform, leveraging Big Pharma castoffs to drive growth beyond its ITP legacy. VEPPANU's U.S. launch targets a $1B ESR1-mutated breast…
benzinga.com HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $85 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and maintains $85 price target.
prnewswire.com Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026 Pooled ARROW and TAPISTRY analysis demonstrated a 53% overall response rate in patients with RET fusion-positive solid tumors Additional analyses highlight first-line clinical outcomes and…
prnewswire.com Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Oct. 2, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc.…
defenseworld.net Reviewing Rigel Pharmaceuticals (NASDAQ:RIGL) & Regeneron Pharmaceuticals (NASDAQ:REGN) Rigel Pharmaceuticals (NASDAQ: RIGL - Get Free Report) and Regeneron Pharmaceuticals (NASDAQ: REGN - Get Free Report) are both healthcare companies, but which is the better investment? We will…
prnewswire.com Rigel to Participate in Upcoming September Investor Conferences SOUTH SAN FRANCISCO, Calif., Sept. 2, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today…
defenseworld.net 18,800 Shares in Rigel Pharmaceuticals, Inc. $RIGL Bought by Canada Pension Plan Investment Board Canada Pension Plan Investment Board acquired a new position in Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) in the second quarter, according to the company in its most recent disclosure with the…
defenseworld.net Connor Clark & Lunn Investment Management Ltd. Buys Shares of 49,096 Rigel Pharmaceuticals, Inc. $RIGL Connor Clark and Lunn Investment Management Ltd. bought a new stake in shares of Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) in the undefined quarter, according to its most recent disclosure with the…
benzinga.com Piper Sandler Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $49 Piper Sandler analyst Allison Bratzel maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Neutral and raises the price target from $40 to $49.
benzinga.com HC Wainwright & Co. Maintains Buy on Rigel Pharmaceuticals, Raises Price Target to $85 HC Wainwright & Co. analyst Joseph Pantginis maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and raises the price target from $57 to $85.
benzinga.com Rigel Pharmaceuticals' VEPPANU For Adults With Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative, Estrogen Receptor 1-Mutated Advanced Or Metastatic Breast Cancer Now Available Via U.S. Prescription VEPPANU is the first and only FDA-approved PROteolysis TArgeting Chimera (PROTAC). PROTACs are a new class of heterobifunctional protein degraders designed to harness the body's natural machinery to…
prnewswire.com Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer VEPPANU is the first and only FDA-approved PROTAC and has the potential to become an important new treatment option for adult patients with 2L+ ER+/HER2-, ESR1-mutated mBC SOUTH SAN FRANCISCO,…
seekingalpha.com Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead Rigel Pharmaceuticals in-licensed Veppanu, a drug for the treatment of certain breast cancer patients, targeting a $1B market, with revenues expected as early as Q3'26. Q2'26 saw strong sales growth…
seekingalpha.com Rigel Pharmaceuticals: The Easy Money Has Been Made (Rating Downgrade) Rigel's Q2 beat big ($78.7M revenue, $0.88 EPS), driven by TAVALISSE, but GAVRETO's year-over-year decline is concerning. Guidance raise came from contract revenue, not accelerating core product…
seekingalpha.com Rigel Pharmaceuticals, Inc. (RIGL) Q2 2026 Earnings Call Transcript Rigel Pharmaceuticals, Inc. (RIGL) Q2 2026 Earnings Call Transcript
marketbeat.com Rigel Pharmaceuticals Q2 Earnings Call Highlights Rigel Pharmaceuticals NASDAQ: RIGL reported second-quarter 2026 total revenue of $78.7 million and net income of $17.3 million, while outlining plans to launch newly licensed breast cancer therapy…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Bluejay Diagnostics (NASDAQ:BJDX) stock moved upwards by 42.0% to $1.42 during Tuesday's after-market session. American Well (NYSE:AMWL) stock rose 12.76% to $11.75. The market value of their…
benzinga.com Rigel Pharmaceuticals Raises FY2026 Sales Guidance from $275.000M-$290.000M to $285.000M-$295.000M vs $308.461M Est Rigel Pharmaceuticals (NASDAQ:RIGL) raises FY2026 sales outlook from $275.000 million-$290.000 million to $285.000 million-$295.000 million vs $308.461 million estimate.
benzinga.com Rigel Pharmaceuticals Q2 EPS $0.88 Beats $0.62 Estimate, Sales $78.700M Beat $69.463M Estimate Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly earnings of $0.88 per share which beat the analyst consensus estimate of $0.62 by 41.94 percent. This is a 73.17 percent decrease over earnings…- benzinga.com Rigel Pharmaceuticals Closes Its Licensing Agreement for VEPPANU; The Agreement Is Effective As Of June 11, 2026 And Rigel Has Made The Upfront Payment Of $70.0M To Be Distributed Evenly Between Arvinas And Pfizer, Consistent With The Terms Of The Agreement Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the closing of its license agreement for VEPPANUTM…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $57 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and maintains $57 price target.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $57 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and maintains $57 price target.
benzinga.com HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $57 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and maintains $57 price target.- benzinga.com Citigroup Maintains Buy on Rigel Pharmaceuticals, Raises Price Target to $81 Citigroup analyst Yigal Nochomovitz maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and raises the price target from $69 to $81.
benzinga.com These Analysts Increase Their Forecasts On Arvinas After Q1 Results Arvinas Inc (NASDAQ:ARVN) reported Q1 losses of 90 cents/share, missed analyst estimates. Rigel Pharmaceuticals (NASDAQ:RIGL) announced global licensing agreement with Arvinas and Pfizer (NYSE:PFE)…
benzinga.com Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer Rigel Pharmaceuticals stock jumps after signing a VEPPANU licensing deal with Arvinas and Pfizer following recent FDA approval.
benzinga.com Arvinas, Pfizer Strike Up To $405M VEPPANU Licensing Deal With Rigel Arvinas, Inc. (NASDAQ:ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, and Pfizer Inc. (NYSE:PFE) have entered into a license agreement with Rigel…- benzinga.com Rigel to Pay $85M Upfront for FDA-Approved VEPPANU; Potential $320M in Milestones Ahead Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that it has entered into an exclusive, global license…
- benzinga.com Citigroup Maintains Buy on Rigel Pharmaceuticals, Lowers Price Target to $69 Citigroup analyst Yigal Nochomovitz maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and lowers the price target from $71 to $69.
- benzinga.com Rigel Pharmaceuticals Affirms FY2026 Sales Guidance of $275.000M-$290.000M vs $284.068M Est Rigel Pharmaceuticals (NASDAQ:RIGL) affirms FY2026 sales outlook from $275.000 million-$290.000 million to $275.000 million-$290.000 million vs $284.068 million estimate.
benzinga.com Rigel Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript - benzinga.com Rigel Pharmaceuticals Q1 EPS $0.44 Misses $0.76 Estimate, Sales $58.800M Miss $62.392M Estimate Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly earnings of $0.44 per share which missed the analyst consensus estimate of $0.76 by 42.11 percent. This is a 30.16 percent decrease over…
benzinga.com Earnings Scheduled For May 5, 2026 - benzinga.com Eli Lilly To Terminate Rigel Collaboration On RIPK1 Inhibitor Ocadusertib Effective June 15, 2026; Does Not Expect Future Milestones Or Royalties Under Agreement After Termination Termination of a Material Definitive Agreement.On April 16, 2026, Rigel Pharmaceuticals, Inc. ("Rigel") received written notice from Eli Lilly and Company ("Lilly") of Lilly's election to terminate…
- benzinga.com FDA Adverse Event Monitoring System Q4 2025 Flags Multiple Potential New Drug Safety Signals, Including Hypersensitivity, Hypogammaglobulinemia, Colitis, Aplastic Anemia And Rhabdomyolysis Under Evaluation https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/october-december-2025-new-safety-information-or-potential-signals-serious-risks-identified-fda
- benzinga.com Rigel Pharmaceuticals Publishes Final Data From Phase 1/2 ARROW Trial Of Pralsetinib To Treat Metastatic Rearranged During Transfection Fusion-Positive Non-Small Cell Lung Cancer Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced publication of the final data from the Phase 1/2…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com Nasdaq Surges Over 1%; ISM Services PMI Tops Views U.S. stocks up on Wednesday with NASDAQ gaining 0.85%. ISM services PMI rose to 56.1. VCI Global Ltd, Latham Group Inc, and Can Fite Biopharma surge.